Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the U.S. Federal Trade Commission (FTC) has filed a complaint seeking to block Sanofi’s exclusive worldwide license agreement for Maze’s glycogen synthase 1 (GYS1) program, including clinical candidate MZE001, which is in development…
Click here to view original post

Advertisement — Advertise with Biotech Networks